Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2111369 Target Snapshot

Inosine-5'-monophosphate dehydrogenase (IMPDH) · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
52Compounds
17Assays
1Approved Drugs
41.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Inosine-5'-monophosphate dehydrogenase (IMPDH) shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P20839. Start with multiple sclerosis, then reuse UniProt P20839 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with multiple sclerosis, then reuse UniProt P20839 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
multiple sclerosis

Inosine-5'-monophosphate dehydrogenase (IMPDH) shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Protein anchor
Inosine-5'-monophosphate dehydrogenase 1

Inosine-5'-monophosphate dehydrogenase 1

Review this target as Inosine-5'-monophosphate dehydrogenase (IMPDH), mapped to UniProt P20839. ChEMBL maps the protein component as Inosine-5'-monophosphate dehydrogenase 1. Sequence length is 514 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P20839 Protein 514 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Inosine-5'-monophosphate dehydrogenase (IMPDH) as ChEMBL target CHEMBL2111369, mapped to UniProt P20839. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Inosine-5'-monophosphate dehydrogenase (IMPDH)
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2111369
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P20839
Inosine-5'-monophosphate dehydrogenase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Inosine-5'-monophosphate dehydrogenase (IMPDH) is the right protein anchor across sources, using UniProt P20839 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why multiple sclerosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameInosine-5'-monophosphate dehydrogenase (IMPDH)
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP20839
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInosine-5'-monophosphate dehydrogenase 1
UniProt AccessionP20839
Component TypeProtein
Sequence Length514 aa

Inosine-5'-monophosphate dehydrogenase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Inosine-5'-monophosphate dehydrogenase (IMPDH), mapped to UniProt P20839. ChEMBL maps the protein component as Inosine-5'-monophosphate dehydrogenase 1. Sequence length is 514 aa.

Mapped IDP20839
Review nameInosine-5'-monophosphate dehydrogenase (IMPDH)
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Inosine-5'-monophosphate dehydrogenase (IMPDH) shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
multiple sclerosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugMYCOPHENOLATE MOFETIL
Linked drugMYCOPHENOLATE SODIUM
Approved-linked Approved
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugMYCOPHENOLATE MOFETIL
Linked drugTHIOGUANINE
Approved-linked Approved
Delayed Graft Function
1 linked drug · 1 direct · 1 efficacy
Linked drugMYCOPHENOLATE MOFETIL
Approved-linked Approved
immune system disease
1 linked drug · 1 direct · 1 efficacy
Linked drugMYCOPHENOLIC ACID
Late clinical Phase III
lupus nephritis
4 linked drugs · 4 direct · 4 efficacy
Linked drugMIZORIBINE
Linked drugMYCOPHENOLATE MOFETIL
Linked drugMYCOPHENOLATE SODIUM
Linked drugMYCOPHENOLIC ACID
Late clinical Phase III
acute graft vs. host disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugMYCOPHENOLATE MOFETIL
Linked drugMYCOPHENOLATE SODIUM
Linked drugMYCOPHENOLIC ACID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemultiple sclerosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5033.0
KI8.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL101754 8.15 IC50 7.0 Preclinical
CHEMBL304087 8.15 IC50 7.0 Clinical
CHEMBL101365 7.7 IC50 20.0 Preclinical
CHEMBL25138 7.4 IC50 40.0 Preclinical
CHEMBL24092 6.75 IC50 180.0 Preclinical
CHEMBL47928 6.7 IC50 200.0 Preclinical
CHEMBL1207374 6.6 Ki 250.0 Preclinical
CHEMBL45658 6.37 IC50 430.0 Preclinical
CHEMBL46358 6.33 IC50 470.0 Preclinical
CHEMBL45504 6.14 IC50 730.0 Preclinical
Distribution

pChEMBL Value Distribution

2
5.0
4
5.5
4
6.0
3
6.5
1
7.0
1
7.5
2
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

17
Total Assays
41
Tested Compounds
2
Assay Types
Binding — 11 assays, 41 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 8 39 5.5
assay format 2 2 5.1
cell-based format 1 0 —
Functional — 6 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine